Summary
(-)DO 710, a substituted benzamide derivative which discriminates dopamine D-2 and D-4 binding sites (Sokoloff et al. 1984), and antagonises in a differential manner several apomorphine-induced behavioral responses (Schwartz et al. 1984) was tritiated and used namely to differentially label the D-4 site.
In striatum the 3H-(-)DO 710 saturation curve was best explained by the presence of two classes of sites with a 7-fold difference in affinity (K d values of 3.0 nM and 0.42 nM) and B max values of 316 and 106 fmol · mg protein−1, respectively which correspond to the D-2 and D-4 sites (Sokoloff et al. 1984).
In spite of its limited selectivity, 3H-(-)DO 710 in low concentration (0.2 nM) could be used to preferentially label striatal D-4 site as shown by the inhibition potencies of discriminant benzamide derivatives (DBD), significantly higher than at pituitary D-2 site (receptor) whereas classical neuroleptics including metoclopramide were equally potent at both sites. The affinity of a variety of agonists for striatal sites labeled with 0.2 nM 3H-(-)DO 710 generally differed from their affinity for the two states of the pituitary D-2 receptor (with high and low affinity for agonists, respectively); compounds like lisuride, N-propylnorapomorphine or pergolide had very high affinity for the striatal 3H-(-)DO 710 site.
In pituitary from oestradiol-treated rats, where only D-2 site occurs, only the low-affinity site for 3H-(-)DO 710 (K d=2.8 nM) was found. In contrast, in the olfactory bulb there was a large proportion of the high-affinity site for 3H-(-)DO 710 since binding occurred with a mean K d value of 0.72 nM.
The effects of a guanylnucleotide [0.1 mM Gpp(NH)p] differed in the three tissues. In pituitary Gpp(NH)p elicited marked effects: i) a 63% increase of specific binding of 0.2 nM 3H-(-)DO 710; ii) a 9-fold increase in the IC50 value of dopamine; iii) a large increase in the pseudo-Hill coefficient of dopamine, so that the latter did not anymore differ from unity. In constrast, Gpp(NH)p produced only marginal changes in olfactory bulb in both the binding of 0.2 nM 3H-(-)DO 710 and its inhibition by dopamine. In striatum, an intermediate and more complex situation was found: Gpp(NH)p i) slightly decreased the mean K d value of 3-H-(-)DO 710 from 1.8 to 1.2 nM; ii) increased by 30% the binding of 0.2 nM 3H-(-)DO 710; iii) decreased by 6-fold the mean affinity of dopamine.
In striatum and olfactory bulb, the pseudo-Hill coefficient of dopamine was not modified by Gpp(NH)p. In addition, at a high 3H-(-)DO 710 concentration (5 nM), where part of the binding presumably occurred at 3H-(-)DO 710 low-affinity site, partial effects of Gpp(NH)p were observed.
It is concluded that sites labeled with high affinity by the DBD 3H-(-)DO 710 in striatum and olfactory bulb are little or not affected by guanylnucleotides and presumably differ from either of the two agonist affinity states of the pituitary D-2 receptor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baudry M, Martres M-P, Schwarz J-C (1979) 3H-domperidone: a selective ligand for dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 308:231–237
Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (K i) and the concentration which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
De Lean A, Kilpatrick BF, Caron M (1982) Dopamine receptor of the porcine anterior pituitary gland. Evidence for two effinity states discriminated by both agonists and antagonists. Mol Pharmacol 22:290–297
Euvrard C, Ferland L, Di Paolo T, Beaulieu M (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary level. Neuropharmacology 19:379–386
Freedman SB, Poat JA, Woodruff GN (1981) Effect of guanine nucleotides on dopaminergic agonist and antagonist affinity for 3H-sulpiride binding sites in rat striatal membrane preparations. J Neurochem 37:608–612
Gulat-Marnay C, Lafitte A, Schwartz J-C (1985) Effects of discriminant and non-discriminant dopamine antagonists on in vivo binding of 3H-propylnorapomorphine in mouse striatum and tuberculum olfactorium. Naunyn-Schmiedeberg's Arch Pharmacol (in press)
Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U, Arvidsson Le, Sevensson U, Nilsson JL (1981) 3-PPP, a centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28:1225–1238
Huff RM, Molinoff PB (1982) Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Proc Natl Acad Sci USA 79:7561–7565
Legan SJ, Allyn Coon G, Karsch FJ (1975) Role of oestrogen as inhibitor of daily LH surges in the ovariectomized rat. Endocrinology 96:50–56
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin reagent. J Biol Chem 193:265–275
Martres M-P, Sokoloff P, Delandre M, Schwartz J-C, Protais P, Costentin J (1984) Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites. Naunyn-Schmiedeberg's Arch Pharmacol 325: 102–115
Parker RB, Waud DR (1971) Pharmacological estimation of drugreceptor dissociation. Statistical evaluation. I. Agonists. J Pharmacol Exp Ther 177:1–12
Protais P, Dubuc I, Costentin J (1983) Pharmacological characteristics of dopamine receptor involved in the dual effects of dopamine agonists on yawning behaviour in rats. Eur J Pharmacol 94:271–280
Protais P, Vasse M, Dubuc I, Costentin J, Sokoloff P, Martres MP, Redounae K, Schwartz JC, Bouthenet ML, Sales N, Hamdi P, Mann A, Wermuth CG (1984) Dopaminergic behavioral responses and classes of binding sites distinguished by discriminant benzamide derivatives. In: Proceed of the Symposium “Dopamine 84” (in press)
Schwarz J-C, Delandre M, Martres M-P, Sokoloff P, Protais P, Vasse M, Costentin J, Laibe P, Wermuth CG, Gulat C, Lafitte A (1984) Biochemical and behavioral identification of discriminant benzamide derivatives: new tools to differentiate subclasses of dopamine receptor. In: Usdin E, Carlsson A, Dahlström A, Engel J (eds) Catecholamines: Neuropharmacology and central nervous system. Alan R Liss, Inc, New York, pp 59–72
Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430
Sibley DR, Creese I (1983) Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol 23:585–593
Sibley DR, De Lean A, Creese I (1982a) Anterior pituitary dopamine receptors. Demonstration of interconvertible high- and low-affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351–6361
Sibley DR, Leff SE, Creese I (1982b) Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sci 31:637–645
Sokoloff P, Martres M-P, Schwarz J-C (1980) Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Naunyn-Schmiedeberg's Arch Pharmacol 315:89–102
Sokoloff P, Martres M-P, Delandre M, Redouane K, Schwartz J-C (1984) 3H-domperidone binding sites differ in rat striatum and pituitary. Naunyn-Schmiedeberg's Arch Pharmacol 327:221–227
Sokoloff P, Brann M, Redouane K, Martres M-P, Schwartz J-C, Bouthenet ML, Sales N, Mann A, Hamdi P, Wermuth CG, Roy J, Morgat J-L (1985) The use of 3H-DO 710 as selective ligand for binding and autoradiographic studies. Eur J Pharmacol 107:243–251
Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366–368
Vasse M, Protais P, Costentin J, Schwartz J-C (1985) Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn-Schmiedeberg's Arch Pharmacol (in press)
Wreggett KA, Seeman P (1984) Agonist high-and low-affinity states of the D-2 dopamine receptor in calf brain. Partial conversion by guanine nucleotide. Mol Pharmacol 25:10–17
Zahniser NR, Molinoff PB (1978) Effects of guanine nucleotides on striatal dopamine receptos. Nature 275:453–454
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sokoloff, P., Redouane, K., Brann, M. et al. 3H-(-)DO 710 discriminates guanine nucleotide sensitive and insensitive dopamine binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 329, 236–243 (1985). https://doi.org/10.1007/BF00501874
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00501874